恩度联合化疗治疗非小细胞肺癌致心血管不良反应的观察

The Observation of Endostatin Combined with Chemotherapy for Non-small Cell Lung Cancer Caused by Cardiovascular Adverse Reactions

目的观察恩度+化疗在非小细胞肝癌(NSCLC)病症治疗中的效果与心血管不良反应发生概率。方法随机将我院收治的68例NSCLC患者分成甲乙两组各34例,分别给予其单纯化疗与恩度+化疗处理,对两组治疗效果与心血管不良反应进行对比分析。结果经统计学分析发现,两组患者在治疗后,均获得了一定成效,其中,甲组治疗总有效率为67.65%,同乙组88.24%相比,差异显著(P<0.05);但恩度联合化疗组未增加化疗药物骨髓抑制等毒性反应,两组在血小板与白细胞改变方面差异无统计学意义(P>0.05);心血管反应发生方面,在窦性心动过速与血压波动方面比较,存在着差异,具有统计学意义(P<0.05)。结论给予临床NSCLC患者以恩度+化疗处理,明显提高其近期治疗效果,出现心血管不良反应在可控范围内,并不会诱发骨髓抑制出现,整体效果理想。

Objective To observe degree ＋ chemotherapy in non-small cell cancer （NSCLC） in the treatment of disease and cardiovascular adverse reaction probability. Method Randomly to our hospital 68 cases of NSCLC patients into two groups of the 34 cases, party a and party b respectively given the simple chemotherapy and grace degrees plus chemotherapy treatment, the effect of two groups of treatment and cardiovascular adverse reactions were analyzed.Results Through statistical analysis, two groups of patients after treatment, all obtained certain achievements, among them, the first treatment the total effective rate was 67.65%, compared with group b 88.24%, significant difference （P〈0.05）; But grace MDT group did not increase the chemotherapy drug toxicity reactions such as bone marrow suppression, two groups there was no statistically significant difference in platelet and leucocyte change （P〉0.05）; Cardiovascular reaction, on sinus tachycardia compared with blood pressure fluctuate, there are differences, statistically significant （P〈0.05）. Conclusion Gives grace to the clinical NSCLC patients degree ＋ chemotherapy treatment, improve its recent treatment effect, in cardiovascular adverse reaction under control, does not induce bone marrow suppression, the overall effect is ideal.